Blocking Sphingosine 1‐phosphate Metabolism With Fingolimod Prevents the Progression of Vascular Smooth Muscle Cells Calcification in Chronic Kidney Disease
Journal of Cellular Physiology · 2026
DOI: 10.1002/jcp.70137 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular Physiology, 2026. Verfasst von Najwa Skafi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Univ Lyon, Universite Claude Bernard Lyon 1, UMR CNRS 5246, ICBMS, Lyon, France. Hauptthemen laut MEDLINE: Sphingosine, Lysophospholipids, Fingolimod Hydrochloride, Muscle, Smooth, Vascular. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Université Claude Bernard Lyon 1: Bourse Qualité Recherche 2014, Societé Francophone de Néphrologie, Dialyse et Transplantation (SFNDT) [IRC terminale: 2021, 2024].
Abstract (Originalsprache)
Patients with chronic kidney disease, and particularly those under hemodialysis, are prone to develop cardiovascular complications, mostly due to the exacerbation of vascular calcification. Vascular calcification relies on the transdifferentiation of vascular smooth muscle cells into calcifying cells. Sphingosine 1‐phosphate is a pleiotropic sphingolipid and an important regulator of osteogenesis and the cardiovascular system. Therefore, we explored the role of sphingosine 1‐phosphate metabolism in chronic kidney disease‐derived vascular calcification. Vascular calcification progression in chronic kidney disease and sphingosine 1‐phosphate signaling were examined in calcified vascular smooth muscle cells, in aortic explants, in rats with adenine‐induced chronic kidney disease, as well as in serum from hemodialysis patients. Sphingosine kinase 2 activity and sphingosine 1‐phosphate secretion, under the control of phospholipase D1, were exacerbated in calcified vascular smooth muscle cells. Furthermore, phospholipase D1 knockout mice display significantly less circulating sphingosine 1‐phosphate, supporting intertwined signalization cascades. Overall, sphingosine kinase expression and activity were upregulated in calcified aortic explants and in calcified aortas from rats. Sphingosine 1‐phosphate was increased in the serum of rats with mild vascular calcification. The Food and Drug Administration‐approved immunosuppressant drug fingolimod, a general modulator of S1P metabolism, strongly inhibited calcification in vascular smooth muscle cells and aortic explants. Additionally, fingolimod significantly reduced inflammation, attenuated metabolic syndrome and moderately inhibited aortic calcification in rats. Finally, we demonstrated for the first time that serum sphingosine 1‐phosphate was significantly increased in hemodialysis patients with mild abdominal aortic calcification. Our findings open an unexplored therapeutic option, which is targeting sphingosine 1‐phosphate metabolism, eventually with fingolimod, for the prevention and treatment of vascular calcification in chronic kidney disease patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Univ Lyon, Universite Claude Bernard Lyon 1, UMR CNRS 5246, ICBMS, Lyon, France.
- Genomic and Health Laboratory/PRASE-EDST Campus Rafic Hariri-Hadath-Beirut-Liban, Faculty of Sciences, Lebanese University, Beirut, Lebanon.
- Département de Néphrologie-Dialyse-Nutrition, Centre Hôpital Lyon Sud, Univ Lyon, UCBL, Inserm 1033, Pierre Bénite, France.
- CarMeN Lab, INSERM U1060, INRA U1397, Universite Claude Bernard Lyon 1, Bron, France.
- Universite Jean Monnet Saint-Étienne, INSERM, Mines Saint Etienne, Saint-Étienne, France.
- Cardiovascular Sciences Graduation Program, Fluminense Federal University (UFF), Niterói, Brazil.
ORCID-Profile: Rene Buchet, Milena B Stockler-Pinto, Leyre Brizuela
Förderung
- Université Claude Bernard Lyon 1: Bourse Qualité Recherche 2014
- Societé Francophone de Néphrologie, Dialyse et Transplantation (SFNDT) [IRC terminale: 2021, 2024]
Zitieren
APA
Skafi, N., Pelletier, S., Soulage, C. O., Nahle, S., Da Cruz, B. O., Othmani, R., Briolay, A., Reibel, S., Vitale, N., Hamade, E., Badran, B., Magne, D., Buchet, R., Stockler-Pinto, M. B., Fouque, D., Mebarek, S., & Brizuela, L. (2026). Blocking Sphingosine 1‐phosphate Metabolism With Fingolimod Prevents the Progression of Vascular Smooth Muscle Cells Calcification in Chronic Kidney Disease. Journal of Cellular Physiology. https://doi.org/10.1002/jcp.70137
Vancouver
Skafi N, Pelletier S, Soulage CO, Nahle S, Da Cruz BO, Othmani R, et al. Blocking Sphingosine 1‐phosphate Metabolism With Fingolimod Prevents the Progression of Vascular Smooth Muscle Cells Calcification in Chronic Kidney Disease. Journal of Cellular Physiology. 2026. doi:10.1002/jcp.70137
BibTeX
@article{Skafi2026,
author = {Skafi, Najwa and Pelletier, Solenne and Soulage, Christophe O and Nahle, Sarah and Da Cruz, Beatriz O and Othmani, Rayan and Briolay, Anne and Reibel, Sophie and Vitale, Nicolas and Hamade, Eva and Badran, Bassan and Magne, David and Buchet, Rene and Stockler-Pinto, Milena B and Fouque, Denis and Mebarek, Saida and Brizuela, Leyre},
title = {Blocking Sphingosine 1‐phosphate Metabolism With Fingolimod Prevents the Progression of Vascular Smooth Muscle Cells Calcification in Chronic Kidney Disease},
journal = {Journal of Cellular Physiology},
year = {2026},
doi = {10.1002/jcp.70137}
}
EUVIMED